This study was conducted to evaluate whether a pulmonary rehabilitation program (PRP) is independently associated with survival in patients with idiopathic pulmonary fibrosis (IPF) undergoing lung transplant (L Tx). This quasi-experimental study included 89 patients who underwent L Tx due to IPF. Thirty-two completed all 36 sessions in a PRP while on the waiting list for L Tx (PRP group), and 53 completed fewer than 36 sessions (controls). Survival after L Tx was the main outcome; invasive mechanical ventilation (IMV), length of stay (LOS) in intensive care unit (ICU) and in hospital were secondary outcomes. Kaplan-Meier curves and Cox regression models were used in survival analyses. Cox regression models showed that the PRP group had a reduced 54.0% (hazard ratio = 0.464, 95% confidence interval 0.222–0.970, p = 0.041) risk of death. A lower number of patients in the PRP group required IMV for more than 24 hours after L Tx (9.0% vs. 41.6% p = 0.001). This group also spent a mean of 5 days less in the ICU (p = 0.004) and 5 days less in hospital (p = 0.046). In conclusion, PRP completion halved the risk of cumulative mortality in patients with IPF undergoing unilateral L Tx.
Methods

Study sample. This retrospective quasi-experimental study included patients with IPF who underwent unilateral LTx between January 2007 and June 2015. IPF was diagnosed by multidisciplinary group discussions based on high-resolution computed tomography and/or surgical lung biopsy before LTx, or in the explanted lung showing a UIP pattern according to the 2011 ATS/ERS/JRS/ALAT guidelines.

Of the 464 consecutive LTx candidates who were referred to our quaternary medical center and subsequently listed for LTx, 278 underwent the procedure during the defined period. We then excluded patients with diseases other than IPF, those with bilateral LTx, those who received living donor lobar LTx, those who required invasive mechanical ventilation (IMV) and/or extracorporeal membrane oxygenation (ECMO) before LTx, (Fig. 1), leaving an analytical sample of 89 patients with IPF who were selected for unilateral LTx according to international guidelines. Thirty-six of these patients completed at least 36 sessions in a PRP while on the waiting list for LTx (PRP group), and 53 completed fewer than 36 sessions and were considered controls. This study was approved by the Hospital Santa Casa de Misericordia de Porto Alegre human ethics committee/internal review board with waiver of consent.

Pulmonary rehabilitation program before lung transplantation. The PRP consisted of medical appointments with the transplant team every 2 months, psychiatric evaluations, nutritional counseling, social assistance, and monthly educational lectures. The physical training component of the PRP was administered by two physical therapists, with sessions three times a week, totaling 36 sessions. During this physical training, patients performed a warm-up, muscle strengthening, and aerobic exercises. The warm-up consisted of breathing exercises (respiratory cycle) associated with arm raising. Muscle strengthening was based on arm and leg exercises with an initial load of 30% of one repetition maximum testing and then one set of 10 repetitions per exercise. The load was increased by 0.5 kg every seven sessions according to the patients’ tolerance. Aerobic exercises were performed on a treadmill, beginning at 70% of the speed of the patient on the 6MWD test, with a progressive protocol every 6 minutes for the variable time until 30 minutes was achieved. The speed was increased by 0.3 km/h every seven sessions. The completion of all exercises was limited when the patient reported dyspnea or leg fatigue, indicated by a modified Borg scale score greater than 4, and when the SpO2 reached 92%. When patients presented a SpO2 < 92%, the exercise was not stopped, but the intensity was reduced, and the oxygen flow was increased as an attempt to maintain the effort and incentive the patient to tolerate dyspnea. At the end of each session, patients performed stretching for all the major muscle groups they had worked. During the PRP, all patients received continuous oxygen therapy in accordance with their medical prescriptions, and they were constantly monitored by pulse oximetry to maintain a SpO2 ≥ 92%. The modified Borg scale was used for measuring dyspnea and leg discomfort.

Treatment received after lung transplantation. After LTx, patients were prescribed maintenance immunosuppressive therapy based on the concomitant use of three drugs: comprising cyclosporine or tacrolimus, azathioprine or mycophenolate, and corticosteroids. In some situations, like drug toxicity, patients were switched to an alternative immunosuppressive regimen. The patients performed modified preemptive prophylaxis for cytomegalic infection and antifungal prophylaxis with inhaled amphotericin or voriconazole according to risk stratification.

Pulmonary function tests and questionnaires. Pulmonary function tests were performed at baseline (when the patient was included on the wait list for LTx, before the 36 sessions of PRP) and after the 36 sessions of PRP in accordance with the technical procedures and the acceptability and reproducibility criteria of the American Thoracic Society/European Respiratory Society and the Brazilian Thoracic Association (BTA). All pulmonary function tests were performed in the pulmonary function laboratory of our institution, which is a laboratory certified by the BTA. In addition to pulmonary function tests, the same physical therapists administered...
The ICU (5 days vs. 7 days, p = 0.004) reduced risk of death when compared to controls. Moreover, IMV for more than 24 hours was associated with higher mortality in the PRP group, whereas PRP was a protective factor in the univariate analysis (Table 2).


table1. Characteristics of the study sample at baseline, i.e., upon placement on the wait list for lung transplantation. Note: Data presented as number (frequency), mean ± standard deviation or median [interquartile range]. PRP: pulmonary rehabilitation program, BMI: body mass index, FEV1: forced expiratory volume in the first second, FVC: forced vital capacity, PASP: pulmonary artery systolic pressure, 6MWD: 6-minute walking distance test, IPF: idiopathic pulmonary fibrosis.

| Variables          | Total (N = 89) | Control (n = 53) | PRP (n = 36) | p     |
|--------------------|---------------|-----------------|-------------|-------|
| Male               | 57 (64%)      | 32 (60.3%)      | 25 (69.4%)  | 0.500 |
| Age, y             | 55.93 ± 10.93 | 56.79 ± 10.84   | 54.67 ± 11.08 | 0.958 |
| BMI, kg/m²         | 25.42 ± 3.870 | 25.44 ± 4.110   | 25.39 ± 3.550 | 0.571 |
| FEV1, L            | 1.33 ± 0.54   | 1.26 ± 0.51     | 1.44 ± 0.56  | 0.119 |
| FVC, L             | 1.61 ± 0.50   | 1.56 ± 0.47     | 1.69 ± 0.54  | 0.220 |
| FEV1, %            | 46.16 ± 15.23 | 43.76 ± 15.02   | 49.65 ± 15.07 | 0.078 |
| FVC, %             | 44.33 ± 12.55 | 43.70 ± 12.14   | 45.25 ± 13.25 | 0.570 |
| FEV1/FVC           | 82.33 ± 21.43 | 81.22 ± 24.05   | 83.97 ± 17.03 | 0.556 |
| PASP, mmHg         | 45.80 ± 15.55 | 46.37 ± 16.50   | 44.97 ± 14.25 | 0.682 |
| 6MWD, meters       | 359.36 ± 133.18 | 327.92 ± 140.78 | 404.78 ± 107.79 | 0.007 |
| Oxygen flow, L/min | 5.19 ± 1.65   | 5.02 ± 1.40     | 5.52 ± 2.04  | 0.206 |
| Median time in list, months | 5.1 [2.4–10.7] | 2.7 [1.4–10.7] | 7.6 [4.5–11.4] | 0.133 |
| Follow-up time, years | 2.1 [0.3–4.1] | 1.9 [0.1–3.6] | 2.7 [0.5–4.5] | 0.405 |

Discussion

This study aimed to investigate the contribution of a PRP to the reduction of mortality after unilateral LTx in patients with IPF. We found that completion of a PRP halved the risk of death after LTx in patients with IPF even after adjusting for prolonged IMV. Patients in the PRP group also benefited from less time on IMV and a reduced LOS in the ICU and in hospital.

Patients with extended LOS following lung transplantation more often receive IMV or ECMO for a prolonged time and are also at a higher risk to be colonized by multidrug-resistant bacteria. In our study, only 9.0% of those in the PRP group remained in IMV for more than 24 hours (vs. 41.6% in the control group), which

Data analysis. The primary outcome was survival after LTx. Secondary outcomes were days on IMV, LOS in ICU and LOS in hospital after LTx. Data are presented as absolute and percentage frequencies, mean ± standard deviation (95% confidence interval) or median (interquartile range). The normal distribution of the database was evaluated through the Shapiro-Wilk test. Comparisons of proportions were evaluated by the Chi-square test for categorical variables and the Student’s t-test for continuous variables. Kaplan-Meier curves, compared to log-rank tests, were used for cumulative survival analyzes. P-values < 0.05 were considered significant. Survival analysis was performed using Cox proportional risk regression models: (i) events were defined as time to death; (ii) censored data were used when the event did not occur at the end of the follow-up period. All parameters with a p-value < 0.10 in the univariate analysis were included in a multivariate model and considered statistically significant if the overall p-value was <0.05. The analysis supported the hypothesis of proportional risk. All analyses were performed in the Statistical Package for the Social Sciences software (PASW Statistics for Windows, Version 18.0, SPSS Inc., Chicago, IL, USA).

Results

There were no significant differences observed at baseline between the characteristics of the PRP group and controls, with the exception of the 6MWD (327.92 ± 140.78 vs. 404.78 ± 107.79, p = 0.007) (Table 1). After completion of 36 sessions of PRP, the PRP group showed an improvement in four domains of SF-36 (physical functioning: 13 ± 24, p = 0.002) (Fig. 2). IMV for more than 24 hours in the PRP group also benefited from less time on IMV and a reduced LOS in the ICU and hospital.

Follow-up time, years 2.1 [0.3–4.1] 1.9 [0.1–3.6] 2.7 [0.5–4.5] 0.405
demonstrates the importance of the PRP for the recovery of those patients with IPF undergoing unilateral LTx, in accordance to previous studies in the literature.20,21. Within our knowledge, this is one of the few studies to evaluate the impact of a PRP program in the mortality of patients with IPF after LTx. Our group already demonstrated that multidisciplinary PRP was helpful for patients on the waiting list for LTx, leading to improvements in 6MWD and quality of life.22 However, previously identified risk factors for early mortality such as age (< 55 years), sex (male sex above 65 years) and single-lung transplants22–24 were not associated with prediction of mortality after LTx in our sample. This finding may be related to the fact that the majority of individuals in our sample were under 65 years. Also, there was no significant difference for patients with or without oxygen rate prescription or increased rate during workout regimen.

Table 2. Cox regression analysis for mortality after unilateral lung transplantation (N = 89). Note: *All parameters at a significance level of p-value less than 0.10 in the univariate analysis were included in a multivariable model; bModel adjusted for PRP and IMV time > 24 hours. PRP: pulmonary rehabilitation program, HR: hazard ratio, CI: confidence interval, BMI: body mass index, FEV1: forced expiratory volume in the first second, FVC: forced vital capacity, PSAP: pulmonary artery systolic pressure, 6MWD: 6-minute walk distance, IMV: invasive mechanical ventilation, ICU: intensive care unit, LOS: length of stay.

Figure 2. Kaplan-Meier curves of cumulative survival of patients stratified by PRP status after lung transplantation. PRP = pulmonary rehabilitation program.
probably have better outcomes and result in an additional source of bias. This is an important limitation of our paper; future investigations should aim to include patients undergoing bilateral LTx as well.

Our study has other limitations, including its quasi-experimental design. Randomization in terms of completion of a PRP is quite difficult now that it has become a well-recognized form of treatment for chronic respiratory diseases, and improvement in physical conditioning has shown to be beneficial for patients pre-transplant. Thus, the design and lack of randomization could be potential sources of selection bias. However, the two groups were homogeneous in regard to most baseline characteristics, except for baseline 6WMD – which was not related to survival benefit in the main analysis. Other variables not included in the present study (e.g., donor variables, cardiopulmonary exercise test, etc.) were already shown to predict survival in the literature and were not available for the present study.

In conclusion, completion of a PRP halved the risk of cumulative mortality in patients with IPF undergoing unilateral LTx, after adjusting for prolonged time (>24 hours) on IMV. Moreover, the PRP group had a reduced risk of prolonged IMV, LOS in the ICU, and total LOS in hospital. Further studies including other recipient diseases and donor variables should be performed in order to confirm PRP as an independent predictor of survival in all kinds of recipients.

Data Availability
The dataset is fully available from the corresponding author on reasonable request.

References
1. Raghu, G. Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years. *Eur. Respir. J.* **50** (2002).
2. Raghu, G. *et al.* An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *Am. J. Respir. Crit. Care Med.* **183**, 788–824 (2011).
3. Caminati, A. *et al.* Severe idiopathic pulmonary fibrosis: what can be done? *Eur. Respir. Rev.* **26** (2017).
4. Dowman, L., Hill, C. J. & Holland, A. E. Pulmonary rehabilitation for interstitial lung disease. *Cochrane Database of Systematic Reviews* (2014).
5. Dowman, L. M. *et al.* The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial. *Thorax* **72**, 610–619 (2017).
6. Wickerson, L. *et al.* Physical rehabilitation for lung transplant candidates and recipients: An evidence-informed clinical approach. *World J. Transplant* **6**, 517–531 (2016).
7. Li, M., Mathur, S., Chowdhury, N. A., Helm, D. & Singer, L. G. Pulmonary rehabilitation in lung transplant recipients. *Chest* **146**, 1087–1096 (2014).
8. Gloeckl, R., Halle, M. & Kenn, K. (2012). Interval versus continuous training in lung transplant candidates: a randomized trial. *J. Heart Lung Transplant.* **31**, 934–941 (2012).
9. Banga, A. *et al.* Hospital length of stay after lung transplantation: Independent predictors and association with early and late survival. *J. Heart Lung Transplant.* **36**, 289–296 (2016).
10. Orens, J. B. *et al.* International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. *J. Heart Lung Transplant.* **25**, 745–755 (2006).
11. Floreth, T. & Bhorade, S. M. Current trends in immunosuppression for lung transplantation. *Semin. Respir. Crit. Care Med.* **31**, 172–178 (2).
12. Monforte, V. *et al.* Risk factors, survival, and impact of prophylaxis length in cytomegalovirus-seropositive lung transplant recipients: A prospective, observational, multicenter study. *Transpl. Infect. Dis.* **19** (2017).
13. Neoh, C. F. *et al.* Antifungal prophylaxis in lung transplantation. *Int. J. Antimicrob. Agents.* **44**(3), 194–202 (2014).
14. Pellegrino, R. *et al.* Interpretative strategies for lung function tests. *Eur. Respir. J.* **26**, 948–968 (2005).
15. American Thoracic Society. European Respiratory Society. American Thoracic Society/European Respiratory Society/International Multidisciplinary Consensus Classification of the idiopathic interstitial pneumonias. *Am. J. Respir. Crit. Care Med.* **165**, 277–304 (2002).
16. Pereira, C. A., Sato, T. & Rodrigues, S. C. New reference values for forced spirometry in white adults in Brazil. *J. Bras. Pneumol.* **33**, 397–406 (2007).
17. American Thoracic Society. ATS statement: guidelines for the six-minute walk test. *Am. J. Respir. Crit. Care Med.* **166**, 111–117 (2002).
18. Campolina, A. G. & Ciconelli, R. M. [SF-36 and the development of new assessment tools for quality of life]. *Acta Reumatol. Port.* **33**, 127–133 (2008).

| Variables                          | Total (N = 89) | Control (n = 53) | PRP (n = 36) | p      |
|-----------------------------------|---------------|-----------------|-------------|-------|
| IMV > 24 bs.                      | 45 (50.6%)    | 37 (69.8%)      | 8 (22.2%)   | 0.001 |
| Days in ICU                       | 6 [4.5–13]    | 7 [5–19]        | 5 [4–27.5]  | 0.004 |
| Days in hospital                  | 23 [19–33]    | 25 [20–39]      | 20 [17.7–26]| 0.046 |

**Table 3.** Primary and secondary outcomes after unilateral lung transplantation. Note: Data presented as number (frequency), mean ± standard deviation or median [interquartile range]. PRP, pulmonary rehabilitation program; ICU: intensive care unit, LTx: lung transplantation.
19. Dierich, M. et al. The influence of clinical course after lung transplantation on rehabilitation success. *Transpl. Int.* **26**, 322–330 (2013).

20. Komatsu, T. et al. Physical activity level significantly affects the survival of patients with end-stage lung disease on a waiting list for lung transplantation. *Surg. Today* **47**, 1526–1532 (2017).

21. Banga, A. et al. Hospital length of stay after lung transplantation: Independent predictors and association with early and late survival. *J. Heart Lung Transplant.* **36**, 289–296 (2017).

22. Florian, J. et al. Impact of pulmonary rehabilitation on quality of life and functional capacity in patients on waiting lists for lung transplantation. *J. Bras. Pneumol.* **39**, 349–356 (2013).

23. Arango Tomás, E. A., Algar, F. J., Cerezo Madueño, F. & Salvatierra Velázquez, A. Evolution and Risk Factors for Early Mortality After Lung Transplantation for Idiopathic Pulmonary Fibrosis: An Experience of 20 Years. *Transplantation Proceedings* **47**, 2656–2658 (2015).

24. Sheikh, S. L., Hayes, D., Kirkby, S. E., Tobias, J. D. & Tumin, D. Age–dependent Gender Disparities in Post Lung Transplant Survival Among Patients With Idiopathic Pulmonary Fibrosis. *Ann. Thorac. Surg.* **103**, 441–446 (2017).

25. Rubin, A. S. et al. Functional improvement in patients with idiopathic pulmonary fibrosis undergoing single lung transplantation. *J. Bras. Pneumol.* **41**, 299–304 (2015).

26. Christie, J. D. et al. The Registry of the International Society for Heart and Lung Transplantation Twenty-sixth Official Adult Lung and Heart-Lung Transplantation Report-2009. *J. Heart Lung Transplant.* **28**, 1031–1049 (2009).

**Author Contributions**

J.F., G.W., P.J.Z.T., J.S.M. designed the study; J.F., L.B.S., D.Z.N. acquired the data; G.W., S.A. analyzed the data; J.F. drafted the manuscript; J.F., S.M.S., L.B.S., D.Z.N., S.M.C., F.A.P., J.J.C., J.C.F. performed procedures and the rehabilitation program; P.J.Z.T., S.A., S.M.S., F.A.P., J.J.C., J.C.F., J.S.M. critically reviewed and edited the manuscript. All approved the final version of the manuscript.

**Additional Information**

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019